Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive?
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene’s viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Part One – Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?
Read Now »
Part Two – A Pharmaceutical Industry Insider’s Claims of Massive Fraud Against 340B Providers
Read Now »
Part Three – The Path From Thalidomide, to Revlimid, to a 340B Whistleblower Lawsuit
Read Now »
Part Four – How Do Celgene’s Revlimid Policies Affect 340B Hospitals and Patient Care?
Read Now »
Part Five – Revlimid “didn’t get any better…. You just got better at making money”
Read Now »
Part Six – What Happens Next For Revlimid, Pomalyst, Thalomid, and 340B?
Read Now »
Follow-up – Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price Read Now »
